BioCentury | Dec 27, 2016
Clinical News

BTI320: Ph II SG01 data

...and significantly reduced mean post-meal maximum glucose (p=0.03) vs. placebo. Boston Therapeutics markets BTI320 as SugarDown...
...glycemic health. Boston Therapeutics Inc. (OTCQB:BTHE), Lawrence, Mass. Product: BTI320 ( BTI-320 , SugarDown) (formerly PAZ320...
...blood glucose and HbA1c Status: Phase II data Milestone: NA Chris Lieu BTI-320 Boston Therapeutics Inc. Acid alpha glucosidase (GAA) BTI320 SugarDown...
BioCentury | Nov 24, 2014
Clinical News

BTI-320: Phase IIb data

...patients responded to BTI-320 with up to a 34% reduction in post-meal blood glucose levels. BTI-320...
...tolerated with no adverse events reported. Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H. Product: BTI-320 (formerly PAZ320...
BioCentury | Sep 1, 2014
Clinical News

BTI-320: Completed Phase IIb enrollment

...trial evaluating BTI-320 for 3 months. Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H. Product: BTI-320 (formerly PAZ320...
BioCentury | Mar 10, 2014
Clinical News

BTI-320: Phase II start

...Boston Therapeutics will begin a double-blind, placebo-controlled, 3-way crossover, U.S. Phase II trial to evaluate BTI-320...
...who are being treated with metformin. Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H. Product: BTI-320 (formerly PAZ320...
BioCentury | Nov 18, 2013
Clinical News

PAZ320: Phase IIb started

...Boston Therapeutics began a double-blind, placebo-controlled, French Phase IIb trial to evaluate PAZ320 in 24 Type...
...24 Type II diabetics being treated with metformin. Boston Therapeutics Inc. (OTCQB:BTHE), Manchester, N.H. Product: PAZ320...
BioCentury | Mar 4, 2013
Clinical News

PAZ320: Additional Phase II data

...portion of an open-label, crossover, dose-escalation Phase I/II trial showed 45% of patients receiving high-dose PAZ320...
...hypoglycemia. Patients received 75 g of jasmine rice alone or with 8 or 16 mg PAZ320...
...g dose of PAZ320 this year. Last April, interim data from the trial showed that PAZ320...
BioCentury | Apr 30, 2012
Clinical News

PAZ320: Phase I/II data

...the Phase II portion of an open-label, dose-escalation Phase I/II trial showed that 0.5 g PAZ320...
...enroll up to 30 patients in the trial. Boston Therapeutics Inc. (OTCBB:BTHE), Manchester, N.H. Product: PAZ320...
BioCentury | Oct 17, 2011
Clinical News

PAZ320: Phase I/II started

...Boston Therapeutics began a U.S. Phase I/II trial to evaluate PAZ320 in 240 diabetics taking either...
...240 diabetics taking either oral agents or insulin. Boston Therapeutics Inc. , Manchester, N.H. Product: PAZ320...
Items per page:
1 - 8 of 8